Nrx pharmaceuticals announces favorable, new safety report for zyesami® (aviptadil) in nih sponsored activ-3b critical care study in patients with life-threatening covid-19

Radnor, pa., nov. 2, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp), a clinical-stage, biopharmaceutical company, today provided a new safety update on zyesami® (aviptadil), which is being tested in the activ-3b critical care phase 3 study sponsored by the national institutes of health.
NRXP Ratings Summary
NRXP Quant Ranking